Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

References

• O’Meara WP, Bejon P, Mwangi TW, Okiro EA, Peshu N, Snow RW, et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008; 372:1555 - 62; http://dx.doi.org/10.1016/S0140-6736(08)61655-4; PMID: 18984188
   PubMed Web of Science ®Google Scholar
• Roberts L, Enserink M. Malaria. Did they really say ... eradication?. Science 2007; 318:1544 - 5; http://dx.doi.org/10.1126/science.318.5856.1544; PMID: 18063766
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455 - 67; http://dx.doi.org/10.1056/NEJMoa0808859; PMID: 19641202
   PubMed Web of Science ®Google Scholar
• Trape JF, Tall A, Diagne N, Ndiath O, Ly AB, Faye J, et al. Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study. Lancet Infect Dis 2011; 11:925 - 32; http://dx.doi.org/10.1016/S1473-3099(11)70194-3; PMID: 21856232
   PubMed Web of Science ®Google Scholar
• Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011; 11:57 - 64; http://dx.doi.org/10.1038/nri2902; PMID: 21179119
   PubMed Web of Science ®Google Scholar
• Plowe CV, Alonso P, Hoffman SL. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis 2009; 200:1646 - 9; http://dx.doi.org/10.1086/646613; PMID: 19877844
   PubMed Web of Science ®Google Scholar
• First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. N Engl J Med 2011;
   Web of Science ®Google Scholar
• Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci 2011; 366:2806 - 14; http://dx.doi.org/10.1098/rstb.2011.0091; PMID: 21893544
   PubMed Web of Science ®Google Scholar
• Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest 2010; 120:4168 - 78; http://dx.doi.org/10.1172/JCI44423; PMID: 21123952
   PubMed Web of Science ®Google Scholar
• Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008; 9:725 - 32; http://dx.doi.org/10.1038/ni.f.205; PMID: 18563083
   PubMed Web of Science ®Google Scholar
• Anders RF, Adda CG, Foley M, Norton RS. Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum. Hum Vaccin 2010; 6:39 - 53; http://dx.doi.org/10.4161/hv.6.1.10712; PMID: 20061790
   PubMed Web of Science ®Google Scholar
• Hill AV, Reyes-Sandoval A, O’Hara G, Ewer K, Lawrie A, Goodman A, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010; 6:78 - 83; http://dx.doi.org/10.4161/hv.6.1.10116; PMID: 20061802
   PubMed Web of Science ®Google Scholar
• Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 2010; 6:97 - 106; http://dx.doi.org/10.4161/hv.6.1.10396; PMID: 19946222
   PubMed Web of Science ®Google Scholar
• Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci 1973; 266:169 - 77; http://dx.doi.org/10.1097/00000441-197309000-00002; PMID: 4583408
   PubMed Web of Science ®Google Scholar
• Ellis RD, Sagara I, Doumbo O, Wu Y. Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccin 2010; 6:627 - 34; http://dx.doi.org/10.4161/hv.6.8.11446; PMID: 20519960
   PubMed Web of Science ®Google Scholar
• Goodman AL, Draper SJ. Blood-stage malaria vaccines - recent progress and future challenges. Ann Trop Med Parasitol 2010; 104:189 - 211; http://dx.doi.org/10.1179/136485910X12647085215534; PMID: 20507694
   PubMed Web of Science ®Google Scholar
• Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, Batchelor AH, et al. High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One 2009; 4:e8138; http://dx.doi.org/10.1371/journal.pone.0008138; PMID: 19997632
   PubMed Web of Science ®Google Scholar
• Singh S, Miura K, Zhou H, Muratova O, Keegan B, Miles A, et al. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 2006; 74:4573 - 80; http://dx.doi.org/10.1128/IAI.01679-05; PMID: 16861644
   PubMed Web of Science ®Google Scholar
• Boyle MJ, Wilson DW, Richards JS, Riglar DT, Tetteh KK, Conway DJ, et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development. Proc Natl Acad Sci U S A 2010; 107:14378 - 83; http://dx.doi.org/10.1073/pnas.1009198107; PMID: 20660744
   PubMed Web of Science ®Google Scholar
• Gilson PR, Crabb BS. Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. Int J Parasitol 2009; 39:91 - 6; http://dx.doi.org/10.1016/j.ijpara.2008.09.007; PMID: 18952091
   PubMed Web of Science ®Google Scholar
• Persson KE. Erythrocyte invasion and functionally inhibitory antibodies in Plasmodium falciparum malaria. Acta Trop 2010; 114:138 - 43; http://dx.doi.org/10.1016/j.actatropica.2009.05.017; PMID: 19481996
   PubMed Web of Science ®Google Scholar
• Garnham PC. Malarial immunity in Africans; effects in infancy and early childhood. Ann Trop Med Parasitol 1949; 43:47 - 61; PMID: 18121270
   PubMed Web of Science ®Google Scholar
• Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity during primary infection. Am J Trop Med Hyg 1999; 61:Suppl 4 - 19; PMID: 10432041
   PubMed Web of Science ®Google Scholar
• Peters J, Fowler E, Gatton M, Chen N, Saul A, Cheng Q. High diversity and rapid changeover of expressed var genes during the acute phase of Plasmodium falciparum infections in human volunteers. Proc Natl Acad Sci U S A 2002; 99:10689 - 94; http://dx.doi.org/10.1073/pnas.162349899; PMID: 12142467
   PubMed Web of Science ®Google Scholar
• Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011; 365:1004 - 13; http://dx.doi.org/10.1056/NEJMoa1008115; PMID: 21916638
   PubMed Web of Science ®Google Scholar
• Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One 2008; 3:e1493; http://dx.doi.org/10.1371/journal.pone.0001493; PMID: 18231580
   PubMed Web of Science ®Google Scholar
• Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One 2009; 4:e5254; http://dx.doi.org/10.1371/journal.pone.0005254; PMID: 19390585
   PubMed Web of Science ®Google Scholar
• Genton B, Betuela I, Felger I, Al-Yaman F, Anders RF, Saul A, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002; 185:820 - 7; http://dx.doi.org/10.1086/339342; PMID: 11920300
   PubMed Web of Science ®Google Scholar
• Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 2011; 11:102 - 9; http://dx.doi.org/10.1016/S1473-3099(10)70262-0; PMID: 21237715
   PubMed Web of Science ®Google Scholar
• Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008; 359:2521 - 32; http://dx.doi.org/10.1056/NEJMoa0807381; PMID: 19064627
   PubMed Web of Science ®Google Scholar
• Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis 2011; 11:741 - 9; http://dx.doi.org/10.1016/S1473-3099(11)70100-1; PMID: 21782519
   PubMed Web of Science ®Google Scholar
• Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364:1411 - 20; http://dx.doi.org/10.1016/S0140-6736(04)17223-1; PMID: 15488216
   PubMed Web of Science ®Google Scholar
• Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, et al. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis 2011; 204:9 - 18; http://dx.doi.org/10.1093/infdis/jir222; PMID: 21628653
   PubMed Web of Science ®Google Scholar
• Okiro EA, Al-Taiar A, Reyburn H, Idro R, Berkley JA, Snow RW. Age patterns of severe paediatric malaria and their relationship to Plasmodium falciparum transmission intensity. Malar J 2009; 8:4; http://dx.doi.org/10.1186/1475-2875-8-4; PMID: 19128453
   PubMed Web of Science ®Google Scholar
• Coggeshall LT, Kumm HW. Demonstration of Passive Immunity in Experimental Monkey Malaria. J Exp Med 1937; 66:177 - 90; http://dx.doi.org/10.1084/jem.66.2.177; PMID: 19870655
   PubMedGoogle Scholar
• Cohen S, McGREGOR IA, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961; 192:733 - 7; http://dx.doi.org/10.1038/192733a0; PMID: 13880318
   PubMed Web of Science ®Google Scholar
• Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011; 377:1770 - 6; http://dx.doi.org/10.1016/S0140-6736(11)60360-7; PMID: 21514658
   PubMed Web of Science ®Google Scholar
• Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009; 361:468 - 77; http://dx.doi.org/10.1056/NEJMoa0805832; PMID: 19641203
   PubMed Web of Science ®Google Scholar
• Pombo DJ, Lawrence G, Hirunpetcharat C, Rzepczyk C, Bryden M, Cloonan N, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002; 360:610 - 7; http://dx.doi.org/10.1016/S0140-6736(02)09784-2; PMID: 12241933
   PubMed Web of Science ®Google Scholar
• Edstein MD, Kotecka BM, Anderson KL, Pombo DJ, Kyle DE, Rieckmann KH, et al. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob Agents Chemother 2005; 49:4421 - 2; http://dx.doi.org/10.1128/AAC.49.10.4421-4422.2005; PMID: 16189139
   PubMed Web of Science ®Google Scholar
• Cowen NL, Clancy RL, Tulloch JL, Cripps AW, Alpers MP. Analysis of patterns of growth inhibition of P. falciparum in synchronised cultures induced by serum from children and adults from Madang, Papua New Guinea. Aust J Exp Biol Med Sci 1985; 63:513 - 20; http://dx.doi.org/10.1038/icb.1985.55; PMID: 3911931
   PubMedGoogle Scholar
• Brown GV, Anders RF, Knowles G. Differential effect of immunoglobulin on the in vitro growth of several isolates of Plasmodium falciparum. Infect Immun 1983; 39:1228 - 35; PMID: 6188695
   PubMed Web of Science ®Google Scholar
• Brown GV, Anders RF, Mitchell GF, Heywood PF. Target antigens of purified human immunoglobulins which inhibit growth of Plasmodium falciparum in vitro. Nature 1982; 297:591 - 3; http://dx.doi.org/10.1038/297591a0; PMID: 7045680
   PubMed Web of Science ®Google Scholar
• Mitchell GH, Butcher GA, Voller A, Cohen S. The effect of human immune IgG on the in vitro development of Plasmodium falciparum. Parasitology 1976; 72:149 - 62; http://dx.doi.org/10.1017/S0031182000048459; PMID: 817249
   PubMed Web of Science ®Google Scholar
• Cohen S, Butcher GA, Crandall RB. Action of malarial antibody in vitro. Nature 1969; 223:368 - 71; http://dx.doi.org/10.1038/223368a0; PMID: 4980851
   PubMed Web of Science ®Google Scholar
• Miura K, Zhou H, Diouf A, Tullo G, Moretz SE, Aebig JA, et al. Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized. Vaccine 2011; 29:2255 - 61; http://dx.doi.org/10.1016/j.vaccine.2011.01.043; PMID: 21277408
   PubMed Web of Science ®Google Scholar
• Miura K, Zhou H, Diouf A, Moretz SE, Fay MP, Miller LH, et al. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 2009; 16:963 - 8; http://dx.doi.org/10.1128/CVI.00042-09; PMID: 19439523
   PubMed Web of Science ®Google Scholar
• Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 2005; 73:3677 - 85; http://dx.doi.org/10.1128/IAI.73.6.3677-3685.2005; PMID: 15908397
   PubMed Web of Science ®Google Scholar
• Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193:673 - 5; http://dx.doi.org/10.1126/science.781840; PMID: 781840
   PubMed Web of Science ®Google Scholar
• Vande Waa JA, Jensen JB, Akood MA, Bayoumi R. Longitudinal study on the in vitro immune response to Plasmodium falciparum in Sudan. Infect Immun 1984; 45:505 - 10; PMID: 6378799
   PubMed Web of Science ®Google Scholar
• Bergmann-Leitner ES, Duncan EH, Burge JR, Spring M, Angov E. Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials. Am J Trop Med Hyg 2008; 78:468 - 71; PMID: 18337345
   PubMed Web of Science ®Google Scholar
• Bergmann-Leitner ES, Duncan EH, Mullen GE, Burge JR, Khan F, Long CA, et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg 2006; 75:437 - 42; PMID: 16968918
   PubMed Web of Science ®Google Scholar
• O’Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 2001; 193:1403 - 12; http://dx.doi.org/10.1084/jem.193.12.1403; PMID: 11413195
   PubMed Web of Science ®Google Scholar
• Persson KE, Lee CT, Marsh K, Beeson JG. Development and optimization of high-throughput methods to measure Plasmodium falciparum-specific growth inhibitory antibodies. J Clin Microbiol 2006; 44:1665 - 73; http://dx.doi.org/10.1128/JCM.44.5.1665-1673.2006; PMID: 16672391
   PubMed Web of Science ®Google Scholar
• Wilson DW, Crabb BS, Beeson JG. Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays. Malar J 2010; 9:152; http://dx.doi.org/10.1186/1475-2875-9-152; PMID: 20525251
   PubMed Web of Science ®Google Scholar
• Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, et al. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 2005; 191:264 - 71; http://dx.doi.org/10.1086/426398; PMID: 15609237
   PubMed Web of Science ®Google Scholar
• Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, Angov E. Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies. Malar J 2008; 7:129; http://dx.doi.org/10.1186/1475-2875-7-129; PMID: 18625058
   PubMed Web of Science ®Google Scholar
• Miura K, Zhou H, Moretz SE, Diouf A, Thera MA, Dolo A, et al. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J Immunol 2008; 181:8776 - 83; PMID: 19050299
   PubMed Web of Science ®Google Scholar
• Mlambo G, Kumar N. A modified Plasmodium falciparum growth inhibition assay (GIA) to assess activity of plasma from malaria endemic areas. Exp Parasitol 2007; 115:211 - 4; http://dx.doi.org/10.1016/j.exppara.2006.08.003; PMID: 16987515
   PubMed Web of Science ®Google Scholar
• Patarapotikul J, Tharavanij S, Poonthong C. Multiple strains of Plasmodium falciparum are necessary for the growth inhibition assay. Southeast Asian J Trop Med Public Health 1983; 14:149 - 53; PMID: 6356378
   PubMedGoogle Scholar
• Shi YP, Udhayakumar V, Oloo AJ, Nahlen BL, Lal AA. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am J Trop Med Hyg 1999; 60:135 - 41; PMID: 9988337
   PubMed Web of Science ®Google Scholar
• Duncan CJ, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, Halstead FD, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909. PLoS One 2011; 6:e22271; http://dx.doi.org/10.1371/journal.pone.0022271; PMID: 21799809
   PubMed Web of Science ®Google Scholar
• Mahdi Abdel Hamid M, Remarque EJ, van Duivenvoorde LM, van der Werff N, Walraven V, Faber BW, et al. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques. PLoS One 2011; 6:e20547; http://dx.doi.org/10.1371/journal.pone.0020547; PMID: 21655233
   PubMed Web of Science ®Google Scholar
• Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990; 172:1633 - 41; http://dx.doi.org/10.1084/jem.172.6.1633; PMID: 2258697
   PubMed Web of Science ®Google Scholar
• Chimma P, Roussilhon C, Sratongno P, Ruangveerayuth R, Pattanapanyasat K, Pérignon JL, et al. A distinct peripheral blood monocyte phenotype is associated with parasite inhibitory activity in acute uncomplicated Plasmodium falciparum malaria. PLoS Pathog 2009; 5:e1000631; http://dx.doi.org/10.1371/journal.ppat.1000631; PMID: 19851453
   PubMed Web of Science ®Google Scholar
• Joos C, Marrama L, Polson HE, Corre S, Diatta AM, Diouf B, et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS One 2010; 5:e9871; http://dx.doi.org/10.1371/journal.pone.0009871; PMID: 20360847
   PubMed Web of Science ®Google Scholar
• Crabb BS, Beeson JG. Promising functional readouts of immunity in a blood-stage malaria vaccine trial. PLoS Med 2005; 2:e380; http://dx.doi.org/10.1371/journal.pmed.0020380; PMID: 16266219
   PubMedGoogle Scholar
• Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, et al. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS One 2008; 3:e3557; http://dx.doi.org/10.1371/journal.pone.0003557; PMID: 18958285
   PubMed Web of Science ®Google Scholar
• McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T, et al. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog 2007; 3:e72; http://dx.doi.org/10.1371/journal.ppat.0030072; PMID: 17511516
   PubMed Web of Science ®Google Scholar
• Cheng Q, Lawrence G, Reed C, Stowers A, Ranford-Cartwright L, Creasey A, et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg 1997; 57:495 - 500; PMID: 9347970
   PubMed Web of Science ®Google Scholar
• Lawrence G, Cheng QQ, Reed C, Taylor D, Stowers A, Cloonan N, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine 2000; 18:1925 - 31; http://dx.doi.org/10.1016/S0264-410X(99)00444-2; PMID: 10699342
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997; 336:86 - 91; http://dx.doi.org/10.1056/NEJM199701093360202; PMID: 8988885
   PubMed Web of Science ®Google Scholar
• Walther M, Tongren JE, Andrews L, Korbel D, King E, Fletcher H, et al. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity 2005; 23:287 - 96; http://dx.doi.org/10.1016/j.immuni.2005.08.006; PMID: 16169501
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 2005; 102:4836 - 41; http://dx.doi.org/10.1073/pnas.0406381102; PMID: 15781866
   PubMed Web of Science ®Google Scholar
• Hamid MM, Remarque EJ, El Hassan IM, Hussain AA, Narum DL, Thomas AW, et al. Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques. Malar J 2011; 10:29; http://dx.doi.org/10.1186/1475-2875-10-29; PMID: 21303498
   PubMed Web of Science ®Google Scholar
• Eisen DP, Wang L, Jouin H, Murhandarwati EE, Black CG, Mercereau-Puijalon O, et al. Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals. Malar J 2007; 6:86; http://dx.doi.org/10.1186/1475-2875-6-86; PMID: 17605823
   PubMed Web of Science ®Google Scholar
• Murhandarwati EE, Black CG, Wang L, Weisman S, Koning-Ward TF, Baird JK, et al. Acquisition of invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein 1 in a transmigrant population requires multiple infections. J Infect Dis 2008; 198:1212 - 8; http://dx.doi.org/10.1086/591943; PMID: 18717639
   PubMed Web of Science ®Google Scholar
• Weiss GE, Traore B, Kayentao K, Ongoiba A, Doumbo S, Doumtabe D, et al. The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog 2010; 6:e1000912; http://dx.doi.org/10.1371/journal.ppat.1000912; PMID: 20502681
   PubMed Web of Science ®Google Scholar
• McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS, et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 2008; 3:e3571; http://dx.doi.org/10.1371/journal.pone.0003571; PMID: 18958278
   PubMed Web of Science ®Google Scholar
• Bolad A, Nebié I, Cuzin-Ouattara N, Traore A, Esposito F, Berzins K. Antibody-mediated in vitro growth inhibition of field isolates of Plasmodium falciparum from asymptomatic children in Burkina Faso. Am J Trop Med Hyg 2003; 68:728 - 33; PMID: 12887035
   PubMed Web of Science ®Google Scholar
• Murhandarwati EE, Wang L, Black CG, Nhan DH, Richie TL, Coppel RL. Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam. Infect Immun 2009; 77:4510 - 7; http://dx.doi.org/10.1128/IAI.00360-09; PMID: 19620342
   PubMed Web of Science ®Google Scholar
• Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 2010; 7:e1000218; http://dx.doi.org/10.1371/journal.pmed.1000218; PMID: 20098724
   PubMed Web of Science ®Google Scholar
• Jensen JB, Boland MT, Allan JS, Carlin JM, Vande Waa JA, Divo AA, et al. Association between human serum-induced crisis forms in cultured Plasmodium falciparum and clinical immunity to malaria in Sudan. Infect Immun 1983; 41:1302 - 11; PMID: 6350183
   PubMed Web of Science ®Google Scholar
• Marsh K, Otoo L, Hayes RJ, Carson DC, Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg 1989; 83:293 - 303; http://dx.doi.org/10.1016/0035-9203(89)90478-1; PMID: 2694458
   PubMed Web of Science ®Google Scholar
• Corran PH, O’Donnell RA, Todd J, Uthaipibull C, Holder AA, Crabb BS, et al. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun 2004; 72:6185 - 9; http://dx.doi.org/10.1128/IAI.72.10.6185-6189.2004; PMID: 15385530
   PubMed Web of Science ®Google Scholar
• John CC, O’Donnell RA, Sumba PO, Moormann AM, de Koning-Ward TF, King CL, et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 2004; 173:666 - 72; PMID: 15210830
   PubMed Web of Science ®Google Scholar
• Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, et al. The quantity and quality of African children’s IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria. PLoS One 2009; 4:e7590; http://dx.doi.org/10.1371/journal.pone.0007590; PMID: 19859562
   PubMed Web of Science ®Google Scholar
• Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, et al. In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun 2010; 78:737 - 45; http://dx.doi.org/10.1128/IAI.00960-09; PMID: 19917712
   PubMed Web of Science ®Google Scholar
• Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, Musyoki JN, et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 2009; 77:1917 - 23; http://dx.doi.org/10.1128/IAI.01358-08; PMID: 19223480
   PubMed Web of Science ®Google Scholar
• Bejon P, Ogada E, Peshu N, Marsh K. Interactions between age and ITN use determine the risk of febrile malaria in children. PLoS One 2009; 4:e8321; http://dx.doi.org/10.1371/journal.pone.0008321; PMID: 20037643
   PubMedGoogle Scholar
• Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, Vountasou P, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med 2007; 4:e242; http://dx.doi.org/10.1371/journal.pmed.0040242; PMID: 17676985
   PubMedGoogle Scholar
• Miura K, Perera S, Brockley S, Zhou H, Aebig JA, Moretz SE, et al. Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay. PLoS One 2011; 6:e20947; http://dx.doi.org/10.1371/journal.pone.0020947; PMID: 21695140
   PubMed Web of Science ®Google Scholar
• Holder AA. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 2009; 136:1445 - 56; http://dx.doi.org/10.1017/S0031182009990515; PMID: 19627632
   PubMed Web of Science ®Google Scholar
• Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, et al. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun 2004; 72:1557 - 67; http://dx.doi.org/10.1128/IAI.72.3.1557-1567.2004; PMID: 14977962
   PubMed Web of Science ®Google Scholar
• Miura K, Zhou H, Muratova OV, Orcutt AC, Giersing B, Miller LH, et al. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. Infect Immun 2007; 75:5827 - 36; http://dx.doi.org/10.1128/IAI.00593-07; PMID: 17923516
   PubMed Web of Science ®Google Scholar
• Duncan CJ, Draper SJ. Controlled Human Blood-Stage Malaria Infection: Current Status and Potential Applications. Am J Trop Med Hyg 2012; In press
   PubMedGoogle Scholar
• Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, Hill AV, et al. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 2009; 27:5719 - 25; http://dx.doi.org/10.1016/j.vaccine.2009.07.049; PMID: 19654061
   PubMedGoogle Scholar
• Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005; 191:619 - 26; http://dx.doi.org/10.1086/427243; PMID: 15655787
   PubMed Web of Science ®Google Scholar
• Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg 2004; 71:196 - 201; PMID: 15306710
   PubMed Web of Science ®Google Scholar
• Sanderson F, Andrews L, Douglas AD, Hunt-Cooke A, Bejon P, Hill AV. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008; 78:878 - 83; PMID: 18541763
   PubMed Web of Science ®Google Scholar
• Douglas AD, Andrews L, Draper SJ, Bojang K, Milligan P, Gilbert SC, et al. Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis 2011; 203:1337 - 40; http://dx.doi.org/10.1093/infdis/jir033; PMID: 21459819
   PubMed Web of Science ®Google Scholar
• Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, et al, MSP-1 Malaria Vaccine Working Group. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 2009; 4:e4708; http://dx.doi.org/10.1371/journal.pone.0004708; PMID: 19262754
   PubMed Web of Science ®Google Scholar
• Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 2009; 27:3090 - 8; http://dx.doi.org/10.1016/j.vaccine.2009.03.014; PMID: 19428923
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011; 19:2269 - 76; http://dx.doi.org/10.1038/mt.2011.176; PMID: 21862998
   PubMed Web of Science ®Google Scholar
• Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2011; 2:601; http://dx.doi.org/10.1038/ncomms1615; PMID: 22186897
   PubMed Web of Science ®Google Scholar
• Wilson DW, Fowkes FJ, Gilson PR, Elliott SR, Tavul L, Michon P, et al. Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans. PLoS One 2011; 6:e27705; http://dx.doi.org/10.1371/journal.pone.0027705; PMID: 22110733
   PubMedGoogle Scholar
• Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998; 177:1664 - 73; http://dx.doi.org/10.1086/515331; PMID: 9607847
   PubMed Web of Science ®Google Scholar